Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study

[1]  R. Gold,et al.  114  Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  D. Arnold,et al.  Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years , 2022, Multiple sclerosis.

[3]  D. Arnold,et al.  Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial , 2022, Multiple sclerosis.

[4]  E. Briard,et al.  Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights , 2021, Multiple sclerosis journal - experimental, translational and clinical.

[5]  Thomas E. Nichols,et al.  Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation , 2021, Multiple sclerosis.

[6]  L. Kappos,et al.  Siponimod and Cognition in Secondary Progressive Multiple Sclerosis , 2020, Neurology.

[7]  Baldur P Magnusson,et al.  Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis , 2020, Multiple sclerosis.

[8]  J. DeLuca,et al.  Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues , 2020, The Lancet Neurology.

[9]  R. Viterbo,et al.  Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis , 2019, Scientific Reports.

[10]  B. Demeneix,et al.  The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination , 2018, Multiple sclerosis.

[11]  Ludwig Kappos,et al.  Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study , 2018, The Lancet.

[12]  C. Oreja-Guevara,et al.  Functional Components of Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Investigation , 2017, Front. Neurol..

[13]  M. Trojano,et al.  Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes , 2017, Multiple sclerosis.

[14]  M. Calabrese,et al.  Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study , 2017, Multiple sclerosis.

[15]  H. Genova,et al.  Information processing speed in multiple sclerosis: Past, present, and future , 2017, Multiple sclerosis.

[16]  Lynn D. Hudson,et al.  Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis , 2017, Multiple sclerosis.

[17]  D. Centonze,et al.  Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis , 2016, Journal of Neuroinflammation.

[18]  F. Zipp,et al.  Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology? , 2016, Trends in Neurosciences.

[19]  K. Dev,et al.  The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures , 2016, Journal of Neuroinflammation.

[20]  V. Planche,et al.  Cognitive impairment in a population‐based study of patients with multiple sclerosis: differences between late relapsing−remitting, secondary progressive and primary progressive multiple sclerosis , 2016, European journal of neurology.

[21]  A. Glabinski,et al.  Neural Plasticity in Multiple Sclerosis: The Functional and Molecular Background , 2015, Neural plasticity.

[22]  F. Jacques.  Defining the clinical course of multiple sclerosis: The 2013 revisions , 2015, Neurology.

[23]  N. Gray,et al.  The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate , 2012, British journal of pharmacology.

[24]  M. Rovaris,et al.  Secondary progressive multiple sclerosis: current knowledge and future challenges , 2006, The Lancet Neurology.

[25]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. , 2006, Brain : a journal of neurology.

[26]  Hans Lassmann,et al.  Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.

[27]  M. Pangalos,et al.  Edg8/S1P5: An Oligodendroglial Receptor with Dual Function on Process Retraction and Cell Survival , 2005, The Journal of Neuroscience.

[28]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[29]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[30]  T. Fog,et al.  [Multiple sclerosis; review]. , 1954, Maanedsskrift for praktisk laegegerning og social Medicin.